(+)-Usniacin
(Synonyms: (+)-地衣酸) 目录号 : GC17330
(+)-Usniacin 从地衣中分离出来，结合在 mTOR 的 ATP 结合口袋，并抑制 mTORC1/2 活性。 (+)-Usniacin 抑制 mTOR 下游效应子的磷酸化:Akt (Ser473)、4EBP1、S6K，诱导自噬，具有抗癌活性。 (+)-Usniacin 对许多浮游革兰氏阳性菌具有抗菌活性，包括金黄色葡萄球菌、粪肠球菌和粪肠球菌。
Cas No.:7562-61-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MIC: 0.05 μg/62.5 μl to 3.1 μg/62.5 μl
Microorganisms can colonize a wide variety of medical devices, putting patients at risk for systemic and local infectious complications, including local-site infections, endocarditis, and catheter-related bloodstream infections. (+)-Usniacin is a secondary lichen metabolite that possesses antimicrobial activity against various planktonic gram-positive bacteria.
In vitro: (+)-Usniacin showed antimicrobial activity against the same microorganisms as that of acetone extract. Among the three analogues it was the most active one having quite low MIC values. Furthermore, (+)-Usniacin did not show any activity against A. hydrophila and B. cereus whereas (D)-usnic acid did. On the other hand, (+)-Usniacin was active against Y. enterocolitica whereas (D)-usnic acid was not active [1].
In vivo: No animal in-vivo study has been reproted so far.
Clinical trials: Trials carried out in volunteers showed that mouth-rinse with (+)-Usniacin preparations exerted a selective and long lasting action against S. mutans. The adherence of S. mutans to smooth surfaces was not increased by the presence of subinhibiting concentrations of (+)-Usniacin. These characteristics make (+)-Usniacin a suitable candidate for topical use in oral medicine [2].
References:
[1] Tay T, Türk AO, Yilmaz M, Türk H, Kivanç M. Evaluation of the antimicrobial activity of the acetone extract of the lichen Ramalina farinacea and its (+)-usnic acid, norstictic acid, and protocetraric acid constituents. Z Naturforsch C. 2004 May-Jun;59(5-6):384-8.
[2] Ghione M, Parrello D, Grasso L. Usnic acid revisited, its activity on oral flora. Chemioterapia. 1988 Oct;7(5):302-5.
| Cas No. | 7562-61-0 | SDF | |
| 别名 | (+)-地衣酸 | ||
| Canonical SMILES | CC1=C(C(=C2C(=C1O)C3(C(=CC(=C(C3=O)C(=O)C)O)O2)C)C(=O)C)O | ||
| 分子式 | C18H16O7 | 分子量 | 344.32 |
| 溶解度 | ≥ 8.0mg/mL in DMSO with gentle warming | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet